NCT00099632View on ClinicalTrials.gov

Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy

PHASE2CompletedINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

November 30, 2011

Conditions
HIV Infections
Interventions
DRUG

Emtricitabine/Tenofovir Disoproxil Fumarate

200mg/300mg as one tablet taken orally once daily

DRUG

Lamivudine/Zidovudine

150mg/300mg as one tablet taken orally twice daily

DRUG

Lopinavir/Ritonavir

133.3mg/33.3mg as three capsules taken orally twice daily

DRUG

single dose Nevirapine

one 200 mg tablet taken orally

Trial Locations (8)

2092

Wits Helen Joseph Hospital CRS (Wits HJH CRS), Johannesburg

3610

Durban International CRS, Westville

6110

Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince

411001

Byramjee Jeejeebhoy Government Medical College CRS, Pune

600113

Chennai Antiviral Research and Treatment (CART) CRS, Chennai

Unknown

Blantyre CRS, Blantyre

Kilimanjaro Christian Medical CRS, Moshi

Joint Clinical Research Center (JCRC)/Kampala CRS, Kampala

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00099632 - Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy | Biotech Hunter | Biotech Hunter